Big congrats to the team at Praxis Precision Medicines, Inc. on this exciting milestone! These results mark a meaningful step forward in the pursuit of next-gen therapies for focal epilepsy. #focalepilepsy #epilepsy #clinicaltrials
Today, we announced positive topline results from the phase 2 RADIANT study of vormatrigine in patients with focal epilepsy. Highlighting the potential for vormatrigine as a next-generation therapy for epilepsy. For additional details, read the press release here: https://lnkd.in/eehTtigW #PraxisMedicines #Epilepsy #Biotech #ClinicalTrials #Neurology #FocalEpilepsy
